BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
55.66
-1.78 (-3.10%)
Nov 3, 2026, 4:00 PM EST - Market closed
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
According to 28 analysts polled by S&P Global, BioMarin Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $91.07. The average 1-year stock price forecast is 63.62% higher than the current stock price, while the lowest is $60 (+7.80%) and the highest is $120 (+115.59%).
Price Target: $91.07 (+63.62%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 13 | 14 | 14 | 16 | 16 |
| Buy | 6 | 6 | 6 | 6 | 5 | 5 |
| Hold | 6 | 6 | 7 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 26 | 25 | 27 | 27 | 28 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Hold Reiterates $60 | Hold | Reiterates | $60 | +7.80% | Nov 3, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $97 | Buy | Maintains | $97 | +74.27% | Nov 3, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $120 | Buy | Maintains | $120 | +115.59% | Nov 3, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $86 | Buy | Maintains | $86 | +54.51% | Nov 3, 2026 |
| UBS | UBS | Buy Reiterates $88 | Buy | Reiterates | $88 | +58.10% | Nov 3, 2026 |
Financial Forecast
Revenue This Year
3.87B
from 3.22B
Increased by 20.15%
Revenue Next Year
4.46B
from 3.87B
Increased by 15.18%
EPS This Year
3.02
from 3.15
Decreased by -4.02%
EPS Next Year
6.40
from 3.02
Increased by 111.66%
EPS and Forward PE are based on non-GAAP adjusted numbers.